Duearity (DEAR.ST) Stock Analysis & AI Equity Report
Duearity (DEAR.ST) overview
Duearity (DEAR.ST) stock analysis and AI equity research. For the latest completed financial year, 2023, Duearity reported revenue of SEK 1.7m and operating profit of SEK -25.8m; the year-end share price was 2.22 SEK and market capitalisation was SEK 41.1m. Duearity is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Duearity's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Duearity
Duearity AB is a Swedish medical technology company focused on tinnitus. It develops and sells Tinearity G1, a non-invasive bone-conduction device that delivers white noise behind the ears to help relieve tinnitus symptoms. The company’s business is built around product development, regulatory approvals, and distribution in selected markets.
Generate the Duearity report
Duearity is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Duearity and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.